ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2394

In Rheumatoid Arthritis, Smoking Is Not Primarily Associated With Anti-Citrullinated Protein Antibodies, But With The Presence Of Multiple Autoantibodies

Ammar Muhammad1, Tineke van Wesemael2, Yuta Kochi3, Maria Mjaavatten4, Kirsten Wevers-de-Boer1, Cornelia F. Allaart1, Leendert A. Trouw1, Akari Suzuki3, Kazuhiko Yamamoto5, Annette H.M. van der Helm-van Mil1, Tom W.J. Huizinga1, René E.M. Toes1 and Diane van der Woude1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, 4Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 5Department of Allergy and Rhaumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies and rheumatoid arthritis, pathogenesis, Rheumatoid Factor

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis: Human Etiology and Pathogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Smoking is associated with the presence of several autoantibodies in various autoimmune diseases. In rheumatoid arthritis (RA), smoking has been described to be specifically associated with the presence of anti-citrullinated protein antibodies (ACPA). We investigated whether smoking is specifically associated with ACPA-positive RA, or with autoantibody-positive RA in general.

Methods: A meta-analysis was performed using RA patients from 5 countries: Norway, Sweden, the United Kingdom, the Netherlands and Japan. Complete data on rheumatoid factor (RF)-, ACPA-status and tobacco exposure were available for 6320 RA patients. The odds ratios (ORs) and 95% confidence intervals (95% CIs) associated with the presence of RF, ACPA or both were calculated by logistic regression comparing ever smokers with never smokers, and using the RF-negative ACPA-negative RA patients as the reference category.

Results: There was no significant association between tobacco exposure and seropositive RA in patients who were positive for only one antibody, being either RF (OR 1.04, 0.76 – 1.42) or ACPA (OR 1.00, 0.82 – 1.22). However, smoking was significantly associated with double-positive (RF-positive and ACPA-positive) RA (OR 1.55, 1.20 – 2.00). When double-positive patients were compared to single-positive patients, the effect of the additional presence of RF or ACPA was comparable; OR for RF: 1.42 (1.20 – 1.67), OR for ACPA: 1.50 (1.26 – 1.79).

Conclusion: Smoking is not associated with ACPA-positive RA, but rather with the concurrent presence of RF and ACPA in RA patients. These data indicate that smoking predisposes to the development of multiple autoantibodies, and not exclusively to ACPA-positive RA.


Disclosure:

A. Muhammad,
None;

T. van Wesemael,
None;

Y. Kochi,
None;

M. Mjaavatten,
None;

K. Wevers-de-Boer,
None;

C. F. Allaart,
None;

L. A. Trouw,

Janssen Biologics,

9;

A. Suzuki,
None;

K. Yamamoto,

UCB Pharma, Pfizer, Abbott, BMS, Roche, Chugai, Mitsubishi-Tanabe and Eisai,

5,

UCB Pharma, Pfizer, Abbott, Santen, Mitsubishi-Tanabe and Eisai,

2;

A. H. M. van der Helm-van Mil,
None;

T. W. J. Huizinga,
None;

R. E. M. Toes,
None;

D. van der Woude,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-rheumatoid-arthritis-smoking-is-not-primarily-associated-with-anti-citrullinated-protein-antibodies-but-with-the-presence-of-multiple-autoantibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology